Sartel: Advanced Angiotensin II Receptor Blocker Therapy
Sartel
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.50 | $75.00 (0%) | 🛒 Add to cart |
| 60 | $2.00 | $150.00 $120.00 (20%) | 🛒 Add to cart |
| 90 | $1.50 | $225.00 $135.00 (40%) | 🛒 Add to cart |
| 120 | $1.30 | $300.00 $156.00 (48%) | 🛒 Add to cart |
| 180 | $1.10 | $450.00 $198.00 (56%) | 🛒 Add to cart |
| 270 | $1.00 | $675.00 $270.00 (60%) | 🛒 Add to cart |
| 360 | $0.80
Best per pill | $900.00 $288.00 (68%) | 🛒 Add to cart |
Sartel is a prescription medication belonging to the class of drugs known as angiotensin II receptor blockers (ARBs). Its active pharmaceutical ingredient, Telmisartan, is specifically formulated to manage hypertension (high blood pressure) by selectively blocking the action of angiotensin II, a potent vasoconstrictor. This blockade results in the relaxation of blood vessels, leading to a significant and sustained reduction in systemic arterial pressure. By effectively controlling blood pressure, Sartel plays a crucial role in mitigating the long-term cardiovascular risks associated with chronic hypertension, including stroke, myocardial infarction, and renal impairment. It is indicated for use in adult patients and is available in various strengths to allow for individualized treatment regimens under strict medical supervision.
Features
- Active ingredient: Telmisartan 20mg, 40mg, or 80mg per tablet
- Pharmaceutical class: Selective angiotensin II receptor blocker (ARB AT1 subtype)
- High bioavailability and long elimination half-life (~24 hours) supporting once-daily dosing
- Excipients include meglumine, sodium hydroxide, povidone, and magnesium stearate
- Film-coated tablets for ease of swallowing and stability
- Manufactured under cGMP (current Good Manufacturing Practices) standards
- Available in blister packs of 14, 28, or 30 tablets
Benefits
- Provides consistent 24-hour blood pressure control with a single daily dose, supporting adherence to therapy.
- Reduces the risk of major cardiovascular events, including stroke and heart attack, by effectively managing hypertension.
- Demonstrates a favorable tolerability profile with a low incidence of side effects such as cough compared to ACE inhibitors.
- Offers renal protective benefits in patients with type 2 diabetes and hypertension by reducing proteinuria.
- Does not require dosage adjustment in patients with hepatic impairment, offering flexibility in diverse patient populations.
- Supports overall cardiovascular health by improving endothelial function and reducing left ventricular hypertrophy.
Common use
Sartel (Telmisartan) is primarily prescribed for the treatment of essential hypertension in adults. It may be used as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics (e.g., hydrochlorothiazide), to achieve optimal blood pressure targets. In patients with high cardiovascular risk, particularly those with type 2 diabetes mellitus and documented end-organ damage, Sartel is also indicated to reduce the risk of myocardial infarction, stroke, or cardiovascular death. It is not intended for immediate relief of hypertensive crises and should be used as part of a long-term management strategy under regular medical monitoring.
Dosage and direction
The recommended initial dose of Sartel is 40 mg taken orally once daily. Depending on the patient’s blood pressure response, the dosage may be titrated to 80 mg once daily. For patients with possible depletion of intravascular volume (e.g., those on high-dose diuretics), initiation with a 20 mg dose is advised to minimize the risk of symptomatic hypotension. Sartel may be taken with or without food, though consistency in administration relative to meals is recommended. Tablets should be swallowed whole with a glass of water and not crushed or chewed. Dosage adjustment is not routinely required in elderly patients or those with mild to moderate renal impairment, but caution is advised in severe renal impairment or hemodialysis patients.
Precautions
Patients should be advised to avoid becoming dehydrated while taking Sartel, as volume depletion may increase the risk of hypotension. Regular monitoring of serum potassium levels is recommended, especially in patients with renal impairment, diabetes, or those concomitantly using potassium-sparing diuretics or potassium supplements. Use with caution in patients with bilateral renal artery stenosis or solitary kidney, as ARBs may cause changes in renal function. Sartel is not recommended during pregnancy due to potential fetal harm, and female patients of childbearing potential should use effective contraception. Patients with severe congestive heart failure should be closely monitored for renal function and potassium levels.
Contraindications
Sartel is contraindicated in patients with known hypersensitivity to Telmisartan or any excipients in the formulation. It must not be used during the second and third trimesters of pregnancy due to the risk of causing injury or death to the developing fetus. Concomitant use with aliskiren in patients with diabetes or renal impairment (GFR <60 mL/min/1.73 m²) is contraindicated. It is also contraindicated in patients with severe hepatic impairment (Child-Pugh class C) or biliary obstructive disorders.
Possible side effects
Common adverse reactions (≥1% of patients) may include dizziness, upper respiratory tract infection, back pain, sinusitis, and diarrhea. Less frequently, hypotension, hyperkalemia, increased serum creatinine, angioedema, rash, pruritus, and gastrointestinal disturbances may occur. Rare but serious side effects include acute renal failure, syncope, and abnormal hepatic function. Patients should be advised to seek immediate medical attention if symptoms of angioedema (e.g., swelling of the face, lips, throat, or tongue) occur.
Drug interaction
Sartel may increase the risk of hyperkalemia when used with potassium-sparing diuretics (e.g., spironolactone), potassium supplements, or salt substitutes containing potassium. Concomitant use with other antihypertensive agents may potentiate the blood pressure-lowering effects. NSAIDs (e.g., ibuprofen, naproxen) may reduce the antihypertensive efficacy of Sartel and increase the risk of renal impairment. Lithium levels may increase when co-administered with Sartel, necessitating monitoring. Use with ACE inhibitors or aliskiren is not recommended due to increased risks of hyperkalemia, hypotension, and renal impairment.
Missed dose
If a dose of Sartel is missed, it should be taken as soon as remembered on the same day. If it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one, as this may increase the risk of hypotension or other adverse effects.
Overdose
Symptoms of Sartel overdose may include pronounced hypotension, tachycardia, bradycardia, dizziness, and renal failure. In the event of suspected overdose, symptomatic and supportive treatment should be initiated, including close monitoring of vital signs and electrolyte balance. Hemodialysis is not effective in removing Telmisartan due to its high protein binding. Management should focus on volume expansion with intravenous normal saline and, if necessary, vasopressor therapy under intensive medical supervision.
Storage
Sartel tablets should be stored in the original blister packaging at room temperature (15–30°C or 59–86°F), protected from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Do not store in bathrooms or other areas with high humidity.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or discontinuing any medication. Do not ignore or delay seeking professional medical advice based on information provided here. Individual patient responses to Sartel may vary, and only a licensed physician can determine the appropriate therapy based on a comprehensive clinical assessment.
Reviews
Clinical studies and meta-analyses consistently demonstrate Sartel’s efficacy in reducing systolic and diastolic blood pressure over 24 hours. In a randomized controlled trial involving over 20,000 patients with vascular disease or high-risk diabetes, Telmisartan was shown to significantly reduce the composite endpoint of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure. Patient-reported outcomes often highlight the convenience of once-daily dosing and the low incidence of bothersome side effects such as cough, contributing to high long-term adherence rates. Specialist reviews frequently commend its metabolic neutrality and protective effects in high-risk populations, though individual experiences should always be discussed with a treating physician.